A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Name: A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Published: 2026
License: Public Domain

AstraZeneca · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

cell-therapy multiple-myeloma

newly diagnosed multiple myeloma (ndmm), multiple myeloma, ndmm, azd0120, cell therapy, car-t, durga-6, bcma, cd19, transplant eligible, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Related documents